Cowen Inc’s Coherus Oncology CHRS Stock Holding History

Cowen Inc’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,500	Closed	-$41K	–	339
2018 Q3	$41K	Sell	2,500 -1,500	-38%	-$26.6K	﹤0.01%	370
2018 Q2	$56	Buy	+4,000	New	+$57.3K	﹤0.01%	384

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cowen Inc's CHRS Position: Q4 2018 in Review

Cowen Inc sold out of Coherus Oncology (CHRS) in Q4 2018, closing a stake of 2,500 shares — an estimated $41K sold.

Cowen Inc first reported a position in CHRS in Q2 2018 and held it in 2 quarters. The position peaked at $41K in Q3 2018. 111 funds tracked by Wall St. Rank hold CHRS as of Q4 2018.

Cowen Inc reported no remaining Coherus Oncology position as of Q4 2018 after selling out during the quarter.
Cowen Inc sold 2,500 Coherus Oncology shares in Q4 2018, an estimated $41K.
Cowen Inc first reported a position in Coherus Oncology in Q2 2018 and held it in 2 quarters.
Cowen Inc's Coherus Oncology position peaked at $41K in Q3 2018.
111 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2018.

Based on Cowen Inc's 13F filing for Q4 2018, filed 14 Feb 2019.